Par Pharmaceuticals Pleads Guilty to Civil & Criminal Allegations of Off-Label Marketing
Par Pharmaceuticals recently pled guilty in federal court to charges of off-label marketing and will be forced to pay $45 million in order to resolve the company’s criminal and civil liability. Par allegedly promoted its prescription drug, Megace ES, for off-label uses that were not approved as safe or effective […]